Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
The present disclosure provides compositions, enema products, and enema delivery systems used for gastric, gastrointestinal and/or colonic treatments; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
1. An enema product configured for transporting to a remote facility, the enema product comprising a container and a pharmaceutical composition within the container, the pharmaceutical composition formulated for enema delivery directly from the container, wherein the container comprises an oxygen-resistant material, and wherein the pharmaceutical composition comprises saline, a cryoprotectant, and a microbiota of a stool sample comprising anaerobic bacteria, wherein particular bacterial species have not been pre-segregated from the microbiota, wherein the pharmaceutical composition comprises no more than 1% rough particulate matter of the stool sample, wherein the microbiota is in an amount effective for treating a C. difficile infection, and wherein the container is configured to provide a reduced oxygen environment to preserve the anaerobic bacteria.
2. The enema product of claim 1 , wherein the pharmaceutical composition comprises no more than 0.8% rough particulate matter of the stool sample.
3. The enema product of claim 1 , wherein the pharmaceutical composition comprises no more than 0.5% rough particulate matter of the stool sample.
4. The enema product of claim 1 , wherein the pharmaceutical composition comprises no more than 0.3% rough particulate matter of the stool sample.
5. The enema product of claim 1 , wherein the cryoprotectant comprises polyethylene glycol.
6. The enema product of claim 1 , wherein the enema product comprises flexible tubing for delivery of the pharmaceutical composition to a subject.
7. The enema product of claim 1 , wherein the stool sample is derived from a healthy human donor.
8. The enema product of claim 1 , wherein the stool sample has a weight of 50 grams.
9. The enema product of claim 1 , wherein the pharmaceutical composition is frozen.
10. An enema delivery system configured for transporting to a remote facility, the enema delivery system comprising a container, flexible tubing, and a pharmaceutical composition within the container, wherein the pharmaceutical composition is formulated for enema delivery from the container via the flexible tubing, wherein the pharmaceutical composition comprises saline, a cryoprotectant and a preparation of viable uncultured non-pathogenic fecal bacteria comprising anaerobic bacteria, wherein the fecal bacteria are from a stool of a human donor, wherein the container is sealed, wherein the pharmaceutical composition comprises no more than 1% rough particulate matter, wherein the pharmaceutical composition is in an amount effective for treating recurrence of C. difficile infection, and wherein the container is configured to provide a reduced oxygen environment to preserve the anaerobic bacteria.
11. The enema delivery system of claim 10 wherein the cryoprotectant comprises polyethylene glycol.
12. The enema delivery system of claim 10 , wherein the pharmaceutical composition comprises no more than 0.8% rough particulate matter of the stool sample.
13. The enema delivery system of claim 10 , wherein the pharmaceutical composition comprises no more than 0.5% rough particulate matter of the stool sample.
14. The enema delivery system of claim 10 wherein the pharmaceutical composition comprises no more than 0.3% rough particulate matter of the stool sample.
15. The enema delivery system of claim 10 , wherein the container comprises ethylene.
16. The enema delivery system of claim 10 , wherein the container comprises an oxygen-resistant material.
17. The enema delivery system of claim 10 , wherein the stool is derived from a healthy human donor.
18. The enema delivery system of claim 10 , wherein the fecal bacteria are separated from fiber of the stool.
19. The enema delivery system of claim 10 , wherein the pharmaceutical composition is frozen.
20. The enema delivery system of claim 10 , wherein the pharmaceutical composition further comprises an antioxidant.